Bionime Corporation (4737) AI Stock Analysis

Bionime Corporation

(TWSE:4737)

Select Model

Rating:40Underperform

Price Target:TWD 53.00▼(-4.85% Downside)

Action:initiatedcoverage

Date:11/10/26

The score is primarily constrained by weak profitability, sustained losses, and elevated leverage. Technical signals are also unfavorable because the price is below all listed moving averages, while positive MACD and subdued momentum indicators offer only limited support. The negative P/E provides no valuation cushion.

Positive Factors

Improved Cash GenerationThe 2025 rebound in operating cash flow and return to positive free cash flow provide internal funding support despite reported losses. If maintained, stronger cash conversion could help Bionime fund product development, manage obligations, and reduce reliance on external financing.

Negative Factors

Persistent Losses and Margin CompressionThe shift from historical profitability to losses, combined with a sharp gross-margin decline, indicates weakening earnings quality and reduced operating resilience. Unless pricing, product mix, or cost performance improves, lower margins can limit reinvestment, pressure cash generation, and prolong the turnaround.

Bionime Corporation (4737) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 4.34B
Dividend Yield: ―
Average Volume (3M): 79.24K
Price to Earnings (P/E): -13.6
Beta (1Y): 0.22
Revenue Growth: -9.37%
EPS Growth: -132.26%
Country: TW
Employees: 1,111
Sector: General
Sector Strength: 55
Industry: Medical - Instruments & Supplies

Bionime Corporation Business Overview & Revenue Model

Company Description

Bionime Corporation, headquartered in Taichung, Taiwan, specializes in the development, production, and global distribution of medical instruments. The company maintains a significant international presence, serving markets in countries such as China...

Bionime Corporation Financial Statement Overview

Summary

Weak financial performance: revenue and margins declined, operating and net losses persisted, leverage remained elevated, and equity fell. Improved 2025 operating and free cash flow provided only limited support.

Income Statement

24Negative

Balance Sheet

36Negative

Cash Flow

31Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.72B	1.84B	1.93B	1.76B	2.21B	1.85B
Gross Profit	561.22M	627.81M	768.38M	715.65M	1.00B	783.13M
EBITDA	-152.56M	-15.08M	59.28M	179.78M	270.36M	248.29M
Net Income	-285.36M	-180.28M	-127.22M	6.21M	91.03M	87.41M
Balance Sheet
Total Assets	5.65B	5.70B	5.78B	5.30B	4.98B	4.56B
Cash, Cash Equivalents and Short-Term Investments	444.78M	485.01M	382.59M	449.21M	277.88M	312.91M
Total Debt	2.66B	3.06B	3.17B	2.82B	2.27B	2.03B
Total Liabilities	3.54B	3.95B	3.89B	3.31B	2.90B	2.49B
Stockholders Equity	2.10B	1.75B	1.88B	1.99B	2.07B	2.07B
Cash Flow
Free Cash Flow	-53.49M	206.41M	-313.29M	-237.95M	-170.63M	-14.85M
Operating Cash Flow	125.88M	494.80M	19.53M	203.44M	142.29M	269.72M
Investing Cash Flow	-194.31M	-286.07M	-336.90M	-435.26M	-312.26M	-288.07M
Financing Cash Flow	76.57M	-108.53M	217.30M	420.40M	113.64M	-69.30M

Bionime Corporation Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:4737 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:1760	64Neutral	TWD 4.23B	24.71	―	4.19%	1.43%	-5.24%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4737	40Underperform	TWD 4.18B	-13.55	―	―	-9.37%	-132.26%
TW:4726	35Underperform	TWD 4.76B	-12.16	―	―	52.81%	38.53%

* General Sector Average

Performance Comparison

TW:4737 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:4737	Bionime Corporation	55.70	-6.00	-9.72%
TW:1271	SunWay Biotech Co., Ltd.	58.80	-2.38	-3.88%
TW:1760	Panion & BF Biotech Inc.	47.70	-17.70	-27.07%
TW:4726	Mycenax Biotech Inc.	22.40	-10.85	-32.63%
TW:6610	TWi Biotechnology, Inc	17.50	-18.80	-51.79%
TW:6634	Sinew Pharma, Inc.	63.20	22.70	56.05%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Bionime Corporation AI Stock Analysis